HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncoethix SA

Division of Merck & Co. Inc.

Latest From Oncoethix SA

Merck’s Oncology Strategy: Digging In With Expansion Of Keytruda

With Keytruda, Merck has shown it has the wherewithal to compete in immuno-oncology against more experienced rivals. Now, as management outlined at ASCO, the company is digging its heels into the field, studying Keytruda in 30 tumor types and evaluating other early stage assets.

BioPharmaceutical Business Strategies

Biopharma Quarterly Dealmaking Statistics, Q4 2014

Biopharma financing increased 53% in Q4 to $8.8 billion; Actavis’ $65 billion takeover of Allergan topped the M&A activity, and Janssen led in dealmaking with six alliances.

BioPharmaceutical Deals

Venture Funding Continues Upward Climb, But On The Backs Of Fewer Investors – BIO Report

Oncology companies have been garnering the most investment from venture capital firms over the last 10 years due to their high levels of innovation, according to a new report from the industry group.

BioPharmaceutical Innovation

Deals Shaping The Medical Industry, January 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Bertrand Damour, CEO
    Esteban Cvitkovic, MD, CSO
    J. Kay Noel, PhD, COO
    Patrice Herait, MD, CMO
  • Contact Info
  • Oncoethix SA
    Phone: 21 616 03 60
    Avenue de l'Elysée 32
    Lausanne, 1006